106 related articles for article (PubMed ID: 16625108)
1. Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography.
Steger-Hartmann T; Graham PB; Müller S; Schweinfurth H
Invest Radiol; 2006 May; 41(5):449-59. PubMed ID: 16625108
[TBL] [Abstract][Full Text] [Related]
2. Toxicological safety evaluation of gadobutrol.
Wack C; Steger-Hartmann T; Mylecraine L; Hofmeister R
Invest Radiol; 2012 Nov; 47(11):611-23. PubMed ID: 23011188
[TBL] [Abstract][Full Text] [Related]
3. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist).
Döhr O; Hofmeister R; Treher M; Schweinfurth H
Invest Radiol; 2007 Dec; 42(12):830-41. PubMed ID: 18007155
[TBL] [Abstract][Full Text] [Related]
4. Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging.
Wible JH; Troup CM; Hynes MR; Galen KP; MacDonald JR; Barco SJ; Wojdyla JK; Periasamy MP; Adams MD
Invest Radiol; 2001 Jul; 36(7):401-12. PubMed ID: 11496095
[TBL] [Abstract][Full Text] [Related]
5. Summary of preclinical safety evaluation of gadoteridol injection.
Soltys RA
Invest Radiol; 1992 Aug; 27 Suppl 1():S7-11. PubMed ID: 1506157
[TBL] [Abstract][Full Text] [Related]
6. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
7. Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance), a new magnetic resonance imaging contrast medium.
Morisetti A; Bussi S; Tirone P; de Haën C
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S207-17. PubMed ID: 10608416
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Safety Assessment of Gadopiclenol: A High-Relaxivity Macrocyclic Gadolinium-Based MRI Contrast Agent.
Gendron C; Bourrinet P; Dencausse A; Fretellier N
Invest Radiol; 2024 Feb; 59(2):108-123. PubMed ID: 37921752
[TBL] [Abstract][Full Text] [Related]
9. Gadocoletic acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography.
de Haën C; Anelli PL; Lorusso V; Morisetti A; Maggioni F; Zheng J; Uggeri F; Cavagna FM
Invest Radiol; 2006 Mar; 41(3):279-91. PubMed ID: 16481911
[TBL] [Abstract][Full Text] [Related]
10. Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents.
Maki JH; Wang M; Wilson GJ; Shutske MG; Leiner T
J Magn Reson Imaging; 2009 Nov; 30(5):1085-92. PubMed ID: 19856442
[TBL] [Abstract][Full Text] [Related]
11. Congenital heart disease: cardiovascular MR imaging by using an intravascular blood pool contrast agent.
Makowski MR; Wiethoff AJ; Uribe S; Parish V; Botnar RM; Bell A; Kiesewetter C; Beerbaum P; Jansen CH; Razavi R; Schaeffter T; Greil GF
Radiology; 2011 Sep; 260(3):680-8. PubMed ID: 21613441
[TBL] [Abstract][Full Text] [Related]
12. Absolute quantification of regional renal blood flow in swine by dynamic contrast-enhanced magnetic resonance imaging using a blood pool contrast agent.
Lüdemann L; Nafz B; Elsner F; Grosse-Siestrup C; Meissler M; Kaufels N; Rehbein H; Persson PB; Michaely HJ; Lengsfeld P; Voth M; Gutberlet M
Invest Radiol; 2009 Mar; 44(3):125-34. PubMed ID: 19151609
[TBL] [Abstract][Full Text] [Related]
13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
14. Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of gadobenate dimeglumine and gadofosveset trisodium.
Iezzi R; Soulez G; Thurnher S; Schneider G; Kirchin MA; Shen N; Pirovano G; Spinazzi A
Eur J Radiol; 2011 Feb; 77(2):358-68. PubMed ID: 19679417
[TBL] [Abstract][Full Text] [Related]
15. A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.
Shamsi K; Yucel EK; Chamberlin P
Invest Radiol; 2006 Nov; 41(11):822-30. PubMed ID: 17035873
[TBL] [Abstract][Full Text] [Related]
16. A multi-center, comparative, phase 3 study to determine the efficacy of gadofosveset-enhanced magnetic resonance angiography for evaluation of renal artery disease.
McGregor R; Vymazal J; Martinez-Lopez M; Neuwirth J; Salgado P; Beregi JP; Peduto A; de la Pena-Almaguer E; Slater GJ; Shamsi K; Parsons EC
Eur J Radiol; 2008 Feb; 65(2):316-25. PubMed ID: 17499952
[TBL] [Abstract][Full Text] [Related]
17. Non-clinical safety assessment of gadoterate meglumine (Dotarem(®)) in neonatal and juvenile rats.
Giorgi H; Ammerman J; Briffaux JP; Fretellier N; Corot C; Bourrinet P
Regul Toxicol Pharmacol; 2015 Dec; 73(3):960-70. PubMed ID: 26382613
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics and general toxicology of iodixanol.
Heglund IF; Michelet AA; Blazak WF; Furuhama K; Holtz E
Acta Radiol Suppl; 1995; 399():69-82. PubMed ID: 8610532
[TBL] [Abstract][Full Text] [Related]
19. Early MR lymphography with gadofluorine M in rabbits.
Misselwitz B; Platzek J; Weinmann HJ
Radiology; 2004 Jun; 231(3):682-8. PubMed ID: 15163808
[TBL] [Abstract][Full Text] [Related]
20. [Reproductive and developmental toxicity study of gadobenate dimeglumine formulation (E7155) (2)--Combined study of effects on fertility and embryo-fetal toxicity in female rats by intravenous administration].
Kawaguchi T; Sagami F; Tirone P; Morisetti A; Bussi S; Baguley JK
J Toxicol Sci; 1999 Nov; 24 Suppl 1():71-8. PubMed ID: 10637781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
